EGFRvIII-targeted alpha therapy (Fusion Pharmaceuticals)

N/A

Report date: 2025/11/21 17:41:03

Base Information

Drug NameEGFRvIII-targeted alpha therapy (Fusion Pharmaceuticals)

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Actinium > 225Ac +[6]

Mechanisms of ActionEpidermal growth factor receptor variant III modulators

TargetsEpidermal growth factor receptor variant III

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFusion Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A